Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B
Locations
Other Locations
Egypt
Mansoura University Hospitals
RECRUITING
Al Mansurah
Contact Information
Primary
Dalia Elsayed Ganady, MBBS
dalia.tawfik97@gmail.com
+201095529264
Backup
Hatem Elalfy, PhD
elalfy2004@mans.edu.eg
+201224790518
Time Frame
Start Date: 2023-08-15
Estimated Completion Date: 2025-08
Participants
Target number of participants: 100
Treatments
Experimental: Anticoagulant in cirrhosis with HCC
HCC patient on anticogulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)
Experimental: Anticoagulant in Cirrhosis without HCC
Benign thrombus in cirrhotic patient on anticoagulant like Enoxaparin (clexan), warfarrin(marivan), or DOAC(apixaban)
No_intervention: No anticoagualnt in Cirrhosis with or without HCC
cirrhotic patients with thrombosis with or without HCC not on anticoagulant
Related Therapeutic Areas
Sponsors
Leads: Mansoura University